Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HIV Vaccine Setback: NIAID Halts PAVE 100 Study, But Smaller Trial Planned

Executive Summary

The National Institute of Allergy and Infectious Diseases will not move forward with plans for its large-scale Phase IIb HIV vaccine study, though a smaller study is being designed to examine viral response, the center announced July 17

You may also be interested in...



It's A Start: Experimental HIV Vaccine Regimen Cuts Disease Risk By A Third In Thai Volunteers

The AIDS vaccine search got its first real injection of good news with a positive trial of a "prime-boost" strategy tested in Thailand

It's A Start: Experimental HIV Vaccine Regimen Cuts Disease Risk By A Third In Thai Volunteers

Six-year U.S. Army/NIH-sponsored study conducted in 16,000-plus Thai adults shows 31.2% decreased risk of infection, but better efficacy is needed.

HIV Vaccine Work Awaits Next STEP In Merck Analysis; Failure Aids Biomarker

Plans for PAVE 100, the National Institute on Allergy and Infectious Diseases' Phase IIb HIV vaccine study, remain on hold until the next wave of Merck's STEP data - also expected to aid preclinical vaccine development - is released, researchers say

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel